{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.645","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"8.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"will be presented as percentage of number of subjects who had the treatment","groups":[{"description":"Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nTbo-filgrastim: Given subcutaneously\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"OG000","title":"Group I (auto HSCT tbo-filgrastim)"},{"description":"Patients undergo auto Hematopoietic Cell Transplantation (HSCT).\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"OG001","title":"Group II (auto HSCT)"}],"paramType":"NUMBER","populationDescription":"Protocol initially stated that number of post discharge granulocyte colony-stimulating factor administrations through day +60 post auto HSCT will be summarized by treatment arm and compared using Wilcoxon rank sum tests up to 60 days; data available is reported as reported as number with G-CSF","reportingStatus":"POSTED","timeFrame":"Up to 60 days","title":"Percentage of Participants With Post Discharge Granulocyte Colony-stimulating Factor Administrations Through Day +60 Post Auto HSCT","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}